During the Bank of America Healthcare Conference in London, Elanco Animal Health President and CEO Jeff Simmons shared updates on the company’s growth initiatives, product launches, and plans for debt reduction. Elanco reported a 10% growth in revenue for the last quarter, evenly distributed between its Farm Animal and Pet Health segments as well as across U.S. and international markets.
Read More
Simmons stated that Elanco aims for mid-single-digit revenue growth, high-single-digit EBITDA growth, and low-double-digit earnings-per-share growth over the next three years. The company is focused on generating $1 billion in cash by 2028, increasing annual margins, and decreasing its leverage, which is currently around six to seven times due to the acquisition of Bayer’s animal health division.
He projected leverage to decline to about three times by the end of this year and into the two-times range in 2024. Regarding pricing, Elanco achieved a 2% increase in the first half of the year, with gains accelerating during July and August, driven by medical differentiation in their products.
A survey of 1,400 U.S. pet owners revealed that 86% plan to maintain or increase their spending on pet health, although some consumers are expected to cut back on food and other products. Simmons noted the lack of a price war in the industry but acknowledged targeted promotions among corporate veterinary groups, where Elanco currently has limited presence.
Elanco is leveraging its over-the-counter sales from the Bayer acquisition through various retail and online platforms, which helps reach price-sensitive consumers. Simmons emphasized the success of Quattro, Elanco’s parasite treatment for dogs, which has exceeded $100 million in sales and has reached more than half of U.S. veterinary clinics. The company plans to expand Quattro internationally next year.
In dermatology, the product Zenrelia is gaining traction, possessing a 10% increase in market share in Europe in the first half of the year. Elanco is also introducing Befrena, a monoclonal antibody treatment for canine dermatology, which is expected to meet high demand and contribute to growth in 2027.
The Farm Animal segment constitutes about half of Elanco's business, benefiting from industry demand for animal protein. Simmons expects growth to continue at a mid-single-digit rate throughout the decade, with the company aiming to invest more in vaccines.
Recently, Elanco acquired AHV, a Dutch nutritional health company for cattle, and plans to focus on debt reduction before considering shareholder returns or further acquisitions. The company anticipates improving its gross margin from the mid-50% range toward 60% and aims for an EBITDA margin to rise from the low-20% range toward 30%. Simmons described the current product opportunities as having significant growth potential as they are globally expanded.
Elanco Animal Health develops products for pets and food-producing animals to prevent disease, control parasites, and enhance overall animal well-being.